Financial Manager
PCI Biotech AS
- Frist 29.5.2022
- Ansettelsesform Fast
PCI Biotech is seeking a Financial Manager
PCI Biotech is seeking a Financial Manager
The Financial Manager position is a high-impact role supporting the Chief Financial Officer (CFO) to drive the financial functions of the company, with significant contributions to external reporting and compliance with all aspects of corporate governance of the company. The role requires good knowledge and experience of IFRS reporting combined with an understanding of the business of innovative technologies.
Job responsibilities
*Drive the operations of the finance function to manage accounts, prepare budgets, monitor and control expenditure, and tax reporting
*Work closely with the CFO for the complete internal and external financial reporting and compliance with corporate governance requirements
*Contribute to other key functions in various aspects of running a small, listed company in an international environment
*Manage external accountants and auditors
*Work closely with colleagues to carry out interdisciplinary assignments as needed and general support across the various functions of the company
The Person
Master’s degree in Business, Finance or Accounting, with at least 3-5 years of working experience in a similar position or auditing, and preferably experience from listed companies and capital market activities. Excellent interpersonal and communications skills while being autonomous, responsive, involved, curious, and open-minded. The ability to apply a risk-based approach in daily work, with an eye for the important details. Good understanding of running a pre-commercial small innovative business.
Location and reporting line
The position is full-time and based at PCI Biotech’s office at Oslo Cancer Cluster Innovation Park and flexibility with regard to working hours is required. The position is reporting to the CFO and PCI Biotech offers a challenging and exciting role in an innovative biotech company.
Om arbeidsgiveren
PCI Biotech’s mission is to improve the lives of cancer patients, by developing and commercialising products based on the company’s innovative PhotoChemical Internalisation (PCI) platform technology.
The company’s lead programme fimaVACC aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through a Phase I study in healthy subjects and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAC programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
- Sektor: Privat
- Lederkategori: Leder
- Sted: 0379 Oslo
- Bransje: Farmasi og legemiddel, Økonomi og regnskap
- Stillingsfunksjon: Økonomi og regnskap
Nøkkelord
Økonomistyring, IFRS, Børs, Corporate governance, Compliance
Annonseinformasjon
- FINN-kode 258032866
- Sist endret